23 enrolling by invitation. 23 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Enrolling by invitation 23 |
| Phase 1 | 6 | Enrolling by invitation 6 |
| Phase 3 | 2 | Enrolling by invitation 2 |
Follow Neurodegenerative Diseases: new trials by email Literature Review of Neurodegenerative Diseases trials Research Report on Neurodegenerative Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 1 | 2026-12-01 | 2026-07-14 |
| Alzheimer's Tau Platform: Regimen A - AADvac1 AADvac1, Donanemab - Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease | Phase 2 | Enrolling by invitation | Paul S. Aisen | 450 | 2026-11-03 | 2026-10-26 |
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France ATH434 - Multiple System Atrophy | Phase 2 | Enrolling by invitation | Alterity Therapeutics | 7 | 2026-10-01 | 2026-10-09 |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab Foralumab Nasal, Placebo - ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis | Phase 2 | Enrolling by invitation | Tiziana Life Sciences LTD | 44 | 2026-09-23 | 2026-10-28 |
| Alzheimer's Disease Research Center (ADRC) PET Component Study 18F-MK6240, 18F-Florbetaben (FBB) - Alzheimer Disease, Mild Cognitive Impairment (MCI) | Phase 2 | Enrolling by invitation | Patrick Lao | 120 | 2026-08-06 | 2026-08-11 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 LM11A-31, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 147 | 2026-07-29 | 2026-08-12 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 AADvac1, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 146 | 2026-07-29 | 2026-08-13 |
| An Extension of SKY-0515 in Participants With Huntington's Disease SKY-0515 - Huntington's Disease (HD) | Phase 2 / Phase 3 | Enrolling by invitation | Skyhawk Therapeutics, Inc. | 500 | 2026-04-10 | 2026-07-24 |
| An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis ML-007C-MA - Psychosis Associated With Alzheimer's Disease | Phase 2 | Enrolling by invitation | MapLight Therapeutics | 210 | 2026-03-25 | 2026-08-07 |
| Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS nL-TARDB-006 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 6 | 2026-02-19 | 2026-08-03 |
| Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients MELATONIN (MELATL07959) - Parkinson Disease | Phase 2 | Enrolling by invitation | Bangladesh Medical University | 70 | 2026-02-17 | 2026-01-29 |
| Tau PET Outcomes With Anti-amyloid Immunotherapies 18F-AV-1451, C-11 ER-176 - Cognitive Impairment, Mild, Dementia, Mild | Phase 2 | Enrolling by invitation | Mayo Clinic | 135 | 2025-11-04 | 2026-10-30 |
| 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome 124I-evuzamitide - Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS) | Phase 2 | Enrolling by invitation | University of Tennessee Graduate School of Medicine | 40 | 2025-05-22 | 2026-07-21 |
| A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I VX-670 - Myotonic Dystrophy Type 1 (DM1) | Phase 2 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 44 | 2025-04-28 | 2026-10-14 |
| Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS nL-CHCHD-001 - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 9 | 2024-10-02 | 2026-07-13 |
| A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI Ginkgo Biloba Extract 761 - Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) | Phase 2 | Enrolling by invitation | Hadassah Medical Organization | 50 | 2024-08-20 | 2025-12-17 |
| Lithium for Parkinson's: an Extension Trial Lithium aspartate - Parkinson Disease | Phase 1 / Phase 2 | Enrolling by invitation | State University of New York at Buffalo | 35 | 2024-08-09 | 2026-10-26 |
| Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia Matching placebo, Dexmedetomidine - Familial Dysautonomia | Phase 2 | Enrolling by invitation | NYU Langone Health | 15 | 2024-07-01 | 2026-04-13 |
| Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy SRP-1003 IV Infusion, Placebo IV Infusion, SRP-1003 SC Injection - Myotonic Dystrophy 1 | Phase 1 / Phase 2 | Enrolling by invitation | Sarepta Therapeutics, Inc. | 78 | 2024-03-04 | 2026-10-05 |
| Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis Efgartigimod IV or Efgartigimod PH20 SC - Generalized Myasthenia Gravis, gMG | Phase 2 / Phase 3 | Enrolling by invitation | argenx | 12 | 2022-08-18 | 2026-04-23 |
Showing 20 of 23. Sign in to see all of them.
Alzheimer Disease (7) · Amyotrophic Lateral Sclerosis (4) · Cognitive Dysfunction (4) · Dementia (4) · Frontotemporal Dementia (2) · Myotonic Dystrophy (2) · Nervous System Diseases (2) · Neuroinflammatory Diseases (2) · Parkinson Disease (2) · Supranuclear Palsy, Progressive (2) · Amyloid Neuropathies, Familial (1) · Amyloidosis (1) · Brain Diseases (1) · Canavan Disease (1)
Nervous System Diseases (21) · Central Nervous System Diseases (17) · Brain Diseases (13) · Mental Disorders (9) · Neurocognitive Disorders (9) · Metabolic Diseases (8) · Neuromuscular Diseases (8) · Nutritional and Metabolic Diseases (8) · Tauopathies (8) · Basal Ganglia Diseases (7) · Movement Disorders (7) · Proteostasis Deficiencies (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Dementia (6)
AADvac1 (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · 8-hydroxyquinazolin-4(3H)-one (1) · ATH434 (1) · Dexmedetomidine (1) · Ginkgo biloba extract (1) · Hematologic Tests (1) · LM11A-31 (1) · Levetiracetam (1) · Melatonin (1) · Prednisone (1) · donanemab (1)
n-Lorem Foundation (3) · Adam Boxer (2) · Mayo Clinic (2) · Alterity Therapeutics (1) · Bangladesh Medical University (1) · Hadassah Medical Organization (1) · MapLight Therapeutics (1) · Myrtelle Inc. (1) · NYU Langone Health (1) · Patrick Lao (1) · Paul S. Aisen (1) · Sarepta Therapeutics, Inc. (1) · Skyhawk Therapeutics, Inc. (1) · State University of New York at Buffalo (1) · Tiziana Life Sciences LTD (1)
United States (18) · France (4) · Australia (3) · Belgium (3) · Canada (3) · Germany (3) · Spain (3) · United Kingdom (3) · Israel (2) · Netherlands (2) · New Zealand (2) · Bangladesh (1) · Bulgaria (1) · Italy (1) · Poland (1)
Adam Boxer, MD, PhD (3) · Anne-Marie Wills, MD (2) · Irene Litvan, MD (2) · Julio Rojas-Martinez, MD, PhD (2) · Alejandra Gonzalez-Duarte, MD (1) · Emily B. Martin, PhD (1) · Farzana Akter, MBBS (1) · Keith Johnson, MD (1) · Neill R Graff-Radford, MD (1) · Patrick J Lao, PhD (1) · Petrice Cogswell, M.D., Ph.D. (1) · Robert Lober, MD, PhD (1) · Thomas Guttuso, MD (1)
2025 (2), R01AG085029 (2), 2023 (1), P30AG066462 (1), P50AG016574 (1), R01AG078457 (1)